🔗 Share this article

As America continues making historic changes to its immunization guidelines, an unexpected name has surfaced unexpectedly: Høeg, an American of Danish descent physician and public health researcher who initially gained attention by questioning COVID-19 vaccines in the global health crisis and has concentrated on alleged deaths after COVID-19 immunization in her brief tenure at the FDA.

Scheduled Changes to Pediatric Vaccine Schedule

Public health authorities planned to announce sweeping revisions to the childhood vaccine schedule earlier this month, bringing the US with the Danish vaccine program, sources say – a substantial departure that would put the US out of alignment with a large portion of the world with little proof for benefit. The announcement has been pushed back until the coming year.

In place of the top vaccines chief, Tracy Beth Høeg is scheduled to speak at the meeting. She was recently named acting director of the FDA’s CDER, the fifth appointee to lead the center this year.

A New Direction at the FDA

The acting appointment may indicate a tighter collaboration between the pharmaceutical and vaccine centers as Høeg and Prasad strengthen their influence at the agency – and it points to a renewed priority upon dismantling already-approved vaccines at the FDA.

Dr. Høeg has frequently advocated for discontinuing some pediatric immunization guidelines in the US in order to be more in line with Denmark, a country with universal health coverage and a citizenry roughly the population of the state of Wisconsin.

So far public appearances, she has continued to focus on vaccination policy – typically the domain of Dr. Prasad, head of the FDA’s Center for Biologics Evaluation and Research (CBER) – as opposed to drug regulation.

Doubts Over Expertise

Dr. Høeg has no apparent track record in medication creation, regulation or leadership, which has been standard for past heads of the Center for Biologics Evaluation and Research. She has been employed at the FDA as a top consultant to the FDA chief and CBER since March.

“She doesn’t seem to have the necessary background” for overseeing the pharmaceutical oversight division, said Dr. Jonathan Howard. “She has not conducted a scientific study. She lacks experience in leading a sizeable institution. She is not an expert in pharmaceutical oversight.”

Past commissioners of CBER would “understand legal statutes and the research of drug development”, said Janet Woodcock. “Objectively, she doesn’t have the kind of background that prior appointees who ran CBER have had.”

The drug center has an immense range of responsibilities at the FDA, Woodcock stated.

“The public just pays attention on the new drug program, but the generic program approves a multitude of off-brand pharmaceuticals. There’s a biosimilars program, over-the-counter program and other areas, and all of those must be supervised,” Dr. Woodcock explained. “The thing you overlook, that’s the thing that I always told people is going to cause problems.”

There is also, a major management component to the role, which oversees more than 5,000 staff members. “It is a huge leadership role, if you do it right,” Woodcock added.

Official Statement and Controversial Programs

When asked about concerns about Høeg’s qualifications and whether this selection represents more teamwork among agency officials on immunizations, a spokesperson said that the “inquiries stem from inaccurate assumptions”.

“This background aligns with the responsibilities of her job,” the official said, noting the months Dr. Høeg spent counseling the FDA commissioner on “medication safety and approval science, including predictive safety algorithms and immunization monitoring”.

As acting director, Høeg takes over the commissioner’s controversial expedited review system, a disputed expedited drug-approval program that apparently concerned her preceding directors. “How are these medications being chosen for this fast-track system? Who makes the decisions?” Dr. Howard asked. “There is a lot of secrecy happening at the FDA right now.”

Overall, he remarked, “the agency appears to be shifting towards less stringent oversight of all drugs, aside from immunizations.”

Established History on Vaccines

With vaccines, Dr. Høeg has a more documented, if concerning, history, some experts said. She released a study using non-validated public submissions to assess the rate of heart inflammation after COVID-19 vaccination. She advised the state of Florida surgeon general Joseph Ladapo, who was said to have changed statistics to indicate Covid vaccinations are riskier than they are.

Among her “desired changes” for the incoming government included changing rules for recently developed shots and halting “unnecessary” vaccines, she remarked post-election on a online show. At the agency, Dr. Høeg has reportedly floated the idea of excluding adolescent males from receiving Covid vaccines.

“She’s an complete true believer who commences with her beliefs and reverse-engineers to retrofit the science in a very misleading, fraudulent manner,” Dr. Howard said.

Gaining Influence and a “Revenge Tour”

Høeg became part of other dissenters, {like|